stockrowUltragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024.
- Revenue
- +8.13%
- EPS
- +36.2%
- Free cash flow
- +12.5%
Quarter to September 2026, against a year earlier
Follow RARE
Alert me
Ultragenyx Pharmaceutical Inc. (RARE) EV/Sales
As of 6 November 2026, Ultragenyx Pharmaceutical Inc. (RARE) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 0.0× (September 2017) to 6,233× (October 2017); the current reading is higher than 24% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | (58.68%) |
| FY2024 | 5.7× | (16.38%) |
| FY2023 | 6.8× | 1.89% |
| FY2022 | 6.7× | (52.53%) |
| FY2021 | 14.1× | (47.02%) |
| FY2020 | 26.6× | 66.35% |
| FY2019 | 16.0× | (51.61%) |
| FY2018 | 33.1× | (95.14%) |
| FY2017 | 681× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.7× | (59.94%) |
| Jun 2026 | 4.3× | 71.52% |
| Mar 2026 | 2.5× | 7.20% |
| Dec 2025 | 2.4× | (42.26%) |
| 36 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BRVE Braveheart Bio, Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. | 1.8× |
| NUVB Nuvation Bio Inc. compare | 5.4× |
| PGEN Precigen, Inc. compare | 10.5× |
| NTLA Intellia Therapeutics, Inc. compare | 20.9× |
| SLS SELLAS Life Sciences Group, Inc. compare | 136× |
| ABSI Absci Corporation compare | 896× |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 5,356× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)